Published in Gene Therapy Weekly, November 25th, 2004
The purchase price was based on a predefined formula included in the original agreement between TKT and the founding European executives.
The company will account for the acquisition of TKT Europe-5S's minority interest as a step acquisition in the fourth quarter of 2004. TKT expects that the majority of the purchase price will be allocated to tangible and intangible assets.
TKT formed TKT...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.